July / August 2021


A closer look at emerging drug-delivery platforms

An update on Port Delivery System with ranibizumab, a large-molecule anti-VEGF candidate and subretinal gene therapy to treat neovascular AMD.

Retinal implant platforms moving from uveitis to AMD

Treatments show potential for various posterior-segment diseases based on their success treating noninfectious uveitis.

Using OCT to evaluate fluid in non-neovascular AMD

How optical coherence tomography, OCT angiography and fluorescein angiography can help direct diagnosis and treatment decisions.

Five emerging treatments show mixed results

Uncertainty about PVL for VMT and aflibercept for NPDR, some clarity on PDT, and early promise for stem cells and a bioresorbable implant.


Clinical Trial Closeup

Targeting headwaters of classical pathway

The IgG antibody fragment ANX007 aims to disrupt the cascade that leads to geographic atrophy at the initiating molecule.

Coding Commentary

Is your ‘new normal’ compliant?

A compliance plan can be more than meeting a mandate. It can improve your operations. Here’s a nuts-and-bolts approach.

Editor's Page


North of the Border

Using a hAM plug for large macular holes

Human amniotic membrane can be a vision-saving option for macular holes larger than 800 µm.

Retina Rounds

A tale of two hydroxychloroquine patients

Two cases demonstrate the spectrum of retinal findings in HCQ retinal toxicity as well as the role of multifocal electroretinogram in detecting the condition.

Social Media Specialist

Agency and advocacy in the digital world

How to utilize social media for patient advocacy and health promotion.

Surgical Pearl Video

Removing thick subretinal PVR bands

Subretinal proliferation is a well-known component of proliferative vitreoretinopathy. Here’s how to deal with it.